التفاصيل البيبلوغرافية
| العنوان: |
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. |
| المؤلفون: |
Huddart, Robert1,2 (AUTHOR) Robert.Huddart@icr.ac.uk, Hafeez, Shaista1,2 (AUTHOR), Lewis, Rebecca1 (AUTHOR), McNair, Helen2 (AUTHOR), Syndikus, Isabelle3 (AUTHOR), Henry, Ann4 (AUTHOR), Staffurth, John5 (AUTHOR), Dewan, Monisha1 (AUTHOR), Vassallo-Bonner, Catalina6 (AUTHOR), Moinuddin, Syed Ali7 (AUTHOR), Birtle, Alison8 (AUTHOR), Horan, Gail9 (AUTHOR), Rimmer, Yvonne10 (AUTHOR), Venkitaraman, Ramachandran11 (AUTHOR), Khoo, Vincent2 (AUTHOR), Mitra, Anita12 (AUTHOR), Hughes, Simon13 (AUTHOR), Gibbs, Stephanie14 (AUTHOR), Kapur, Gaurav15 (AUTHOR), Baker, Angela3 (AUTHOR) |
| المصدر: |
International Journal of Radiation Oncology, Biology, Physics. Jun2021, Vol. 110 Issue 2, p412-424. 13p. |
| مصطلحات موضوعية: |
*BLADDER cancer, *IMAGE-guided radiation therapy, *INTRAVESICAL administration, *CANCER radiotherapy, *CONE beam computed tomography, *CLINICAL trials, *OLDER patients |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
Purpose: Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided radiation therapy delivery could improve outcomes by minimizing the volume of normal tissue irradiated. The HYBRID trial assessed the multicenter implementation, safety, and efficacy of this strategy.Methods: HYBRID is a Phase II randomized trial that was conducted at 14 UK hospitals. Patients with T2-T4aN0M0 muscle-invasive bladder cancer unsuitable for radical therapy received 36 Gy in 6 weekly fractions, randomized (1:1) to standard planning (SP) or adaptive planning (AP) using a minimization algorithm. For AP, a pretreatment cone beam computed tomography (CT) was used to select the POD from 3 plans (small, medium, and large). Follow-up included standard cystoscopic, radiologic, and clinical assessments. The primary endpoint was nongenitourinary Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 (≥G3) toxicity within 3 months of radiation therapy. A noncomparative single stage design aimed to exclude ≥30% toxicity rate in each planning group in patients who received ≥1 fraction of radiation therapy. Local control at 3-months (both groups combined) was a key secondary endpoint.Results: Between April 15, 2014, and August 10, 2016, 65 patients were enrolled (SP, n = 32; AP, n = 33). The median follow-up time was 38.8 months (interquartile range [IQR], 36.8-51.3). The median age was 85 years (IQR, 81-89); 68% of participants (44 of 65) were male; and 98% of participants had grade 3 urothelial cancer. In 63 evaluable participants, CTCAE ≥G3 nongenitourinary toxicity rates were 6% (2 of 33; 95% confidence interval [CI], 0.7%-20.2%) for the AP group and 13% (4 of 30; 95% CI, 3.8%-30.7%) for the SP group. Disease was present in 9/48 participants assessed at 3 months, giving a local control rate of 81.3% (95% CI, 67.4%-91.1%).Conclusions: POD adaptive radiation therapy was successfully implemented across multiple centers. Weekly ultrahypofractionated 36 Gy/6 fraction radiation therapy is safe and provides good local control rates in this older patient population. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
